Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-085 · 1 trial · 4 indications
Collect all adverse events at each visit.
AUC (0-t) = Area under the serum concentration curve from time zero (pre-dose) to the time of the last measurable concentration.
| Arm | Type | Description |
|---|---|---|
| Arm A4 (ABBV-085) | EXPERIMENTAL | ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson |
| Arm A3 (ABBV-085) | EXPERIMENTAL | ABBV-085 will be administered at every cycle (28-day cycles). |
| Name | Type | Description |
|---|---|---|
| ABBV-085 | DRUG | Administered as an intravenous infusion in 28-day dosing cycles. |
Inclusion Criteria: 1. Participants with advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. 3. Participants must have measurable disease per Response Evaluation Criteria In...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABBV-085 is an investigational small molecule being studied for the treatment of advanced solid tumors, including undifferentiated pleomorphic sarcoma, squamous cell carcinoma of the head and neck, and carcinoma of the breast. It is in Phase 1 clinical development and has not been approved by the FDA.
ABBV-085 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is currently in Phase 1 clinical development for advanced solid tumors.
ABBV-085 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 trial has been completed, and the drug remains under investigation for advanced solid tumors.
ABBV-085 has been studied in one clinical trial, NCT02565758, titled 'ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors.' This Phase 1 trial enrolled 85 participants and was completed. The trial was conducted in the United States, France, and Spain.
The clinical trial for ABBV-085 describes it as an antibody drug conjugate, though the drug is also classified as a small molecule. It is being investigated for advanced solid tumors, including undifferentiated pleomorphic sarcoma, squamous cell carcinoma of the head and neck, and breast carcinoma.